Form 4: Iovance Biotherapeutics Executive Frederick G. Vogt Reports Stock Transactions
SEC Form 4 Filing
Frederick G. Vogt, Interim CEO & General Counsel at Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.
Summary
- Frederick G. Vogt, the Interim CEO & General Counsel of Iovance Biotherapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
- On January 14, 2025, 20,835 restricted stock units (RSUs) vested, converting into common stock.
- Following the vesting, 9,955 shares were withheld by the company to cover mandatory tax obligations.
- The remaining 221,116 shares of common stock are now directly owned by Mr. Vogt.
- The transactions did not involve any open market sales.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, which is neither positive nor negative in itself. It reflects standard executive compensation practices.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the ownership changes of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the Securities and Exchange Commission (SEC).
- The reporting of RSU vesting and tax withholding is a common occurrence for executives who receive equity compensation.
- The process and details of this filing are consistent with those of other biotechnology companies and public companies in general.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in ownership by an executive, but does not represent a change in the overall number of shares outstanding.
- The transaction has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/14/2022 | Date of the original RSU grant. |
| 01/14/2025 | Date of RSU vesting and tax withholding. |
| 01/16/2025 | Date the Form 4 was signed. |
Keywords
Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Stock Vesting, Tax Withholding, Iovance Biotherapeutics, IOVA, Frederick G. Vogt, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.